Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have ...

The World Health Organization (WHO) has released updated recommendations on HIV clinical management providing new and revised ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the ...

After four decades of hard-won progress toward curbing the HIV epidemic, the face of the disease is changing.

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...

The global Kaposi’s Sarcoma market is expanding due to the HIV/AIDS prevalence, improved oncology infrastructure, and advancements in targeted and immunotherapeutic drugs. Kaposi’s Sarcoma, a tumor ...